Soleno Therapeutics, Inc. (SLNO)
NASDAQ: SLNO · Real-Time Price · USD
57.78
+3.15 (5.77%)
At close: Nov 22, 2024, 4:00 PM
59.59
+1.81 (3.13%)
After-hours: Nov 22, 2024, 4:02 PM EST
Soleno Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
33
Market Cap
2.49B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Alignment Healthcare | 2.47B |
UFP Technologies | 461.85M |
LeMaitre Vascular | 213.03M |
Geron | 29.48M |
Arrowhead Pharmaceuticals | 19.65M |
Janux Therapeutics | 13.05M |
Centessa Pharmaceuticals | 6.85M |
IDEAYA Biosciences | 3.92M |
SLNO News
- 9 days ago - Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024 - GlobeNewsWire
- 6 weeks ago - Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments - Seeking Alpha
- 6 weeks ago - SLNO Stock Rises as Prader-Willi Treatment Nears FDA Approval - GuruFocus
- 7 weeks ago - Janus Henderson Group PLC's Strategic Acquisition in Soleno Therapeutics Inc - GuruFocus
- 2 months ago - Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Soleno Therapeutics: 2 New Catalysts To Bring Forth Change For PWS Patients - Seeking Alpha
- 3 months ago - Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome - GlobeNewsWire
- 3 months ago - Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire